The second axis of market taxonomy separates Single-use Hemoperfusion Devices by type, reflecting the underlying sorbent technology and cartridge architecture. Polymyxin B‑immobilized cartridges are engineered to bind endotoxin and dominate the sepsis sub‑segment, contributing roughly 30 % of type‑based revenue due to their extensive clinical validation. Cytokine‑adsorbing polymeric cartridges, exemplified by CytoSorb and HA330, target a broader inflammatory spectrum and account for about 28 % of the market, driven by their versatility in liver failure and renal support. Activated‑carbon cartridges specialize in toxin adsorption for poisoning cases, representing close to 22 % of type sales. Hybrid sorbent systems, which combine polymeric and carbon matrices, capture niche applications such as autoimmune modulation and hold an estimated 12 % share. Finally, Emerging nanomaterial‑based cartridges are in early commercial rollout, contributing approximately 8 % but projected to grow as clinical data mature. Each type’s share aligns with its clinical utility, cost structure, and reimbursement landscape, collectively shaping the overall market size. Regulatory pathways differ by sorbent composition, influencing time‑to‑market and pricing, which in turn modulates each type’s contribution to total sales.
